NCT07284758 · C4 Therapeutics, Inc.
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
(MOMENTUM)
What this study is about
This is a Phase 2, where both patients and doctors know the treatment given, single-treatment group$1, conducted at multiple hospitals study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
View original scientific description
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Be willing and able to provide signed informed consent for the study.
- Age ≥ 18 years at the time of signed consent.
- Subjects must have a documented diagnosis of MM and measurable disease at enrollment.
- Received at least 3 prior anti-myeloma regimens (for a minimum of 2 or more consecutive cycles) that must have included an immunomodulatory drug (i.e., IKZF 1/3 degrader), a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager (TCE) or chimeric antigen receptor T-cell (CAR-T) therapy, unless not available per local standard of care.
- Subjects need to have adequate organ function.
- Toxicities from prior anticancer therapies must have resolved to baseline severity or CTCAE ≤ Grade 1.
- Female subjects may not be pregnant or intend to become pregnant, may not breastfeed or intend to breastfeed, or donate ova during their participation in this study until 30 days after the last dose of study treatment.
- Male subjects must agree to use a condom when having intercourse with a person of childbearing potential during the Treatment Period and for at least 30 days after the last dose of study treatment.
- Male subjects must refrain from donating sperm during the Treatment Period and for 30 days after discontinuation.
- Subjects must refrain from donating blood during study treatment and for 30 days after discontinuation.
Exclusion criteria
- Presence of myeloma in the central nervous system (CNS).
- Subjects with any of the following:
- Systemic light chain amyloidosis
- Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes (POEMS) Syndrome
- Myelodysplastic syndrome (MDS).
- Previously treated with cemsidomide.
- Clinically significant impaired cardiac function or cardiac disease.
- Thromboembolic event within 3 months prior to enrollment.
- Known malignancy other than study indication that has progressed or required treatment within the past 3 years.
- Uncontrolled active bacterial, fungal, or viral infection.
- Inability or difficulty swallowing tablets. NOTE: Other inclusion/exclusion criteria may apply, per protocol.
Where
- Scottsdale, Arizona
- West Hollywood, California
- Atlanta, Georgia
- Indianapolis, Indiana
- Grand Rapids, Michigan
- St Louis, Missouri
- Omaha, Nebraska
- New York, New York
- San Antonio, Texas
- Madison, Wisconsin
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 1, 2026 · Source of record for eligibility and locations